• 6분 읽기
• 2025년 8월 28일 게시
안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
Let’s be honest, nobody enjoys a needle. It’s a primal, almost childish aversion, but a powerful one nonetheless. For years, this simple fact has been a frustrating barrier for some of the most effective weight-loss drugs on the planet. The likes of Ozempic and Wegovy have worked wonders, but they’ve always come with the sting of a weekly injection. To me, that always seemed like a commercial vulnerability just waiting to be exploited.
Now, it seems the day of reckoning might be upon us. Eli Lilly, a titan of the pharmaceutical world, has reported rather promising results for its oral drug, orforglipron. Suddenly, the prospect of achieving similar results with a simple pill is no longer a distant dream. This isn't just a tweak or a minor upgrade, it’s a potential earthquake set to rattle a multi-billion pound industry.
If I were a senior executive at Novo Nordisk, the Danish firm behind Ozempic and Wegovy, I might be feeling a tad queasy. They have, for years, been the undisputed kings of the GLP-1 market. They built an empire on the back of injectable treatments, and a mighty profitable one at that. But dominance built on a delivery method that people actively dislike is a fragile sort of power.
Eli Lilly’s move puts Novo Nordisk in a classic bind. Do they rush their own oral version to market and risk cannibalising their own cash cows? Or do they hold firm and hope the convenience of a pill isn't enough to lure patients away? It’s a fascinating strategic dilemma. History teaches us that when a more convenient technology comes along, it almost always wins. Think of streaming services versus video rental shops. The outcome is rarely in doubt, it’s just a matter of when.
Of course, this isn't just a two-horse race. The scent of enormous profits has attracted a whole host of smaller, nimbler biotech firms. Companies like Structure Therapeutics are entirely focused on creating oral alternatives, unburdened by a legacy of injectable products they need to protect. They are the speedboats zipping around the oil tankers, able to pivot and innovate without the corporate inertia that can plague the giants.
From an investor’s perspective, this creates a rather tantalising, if perilous, landscape. Do you back the established behemoth, Eli Lilly, which seems to have a head start? Or do you place a bet on a smaller, more speculative biotech that could, if its trials succeed, deliver explosive returns? There is no simple answer, and the risks are as significant as the potential rewards. To me, this whole saga looks like a classic case of disruption, a theme we've explored in our Beyond The Needle: The Oral GLP-1 Revolution basket.
Ultimately, the biggest winner in all this will likely be the patient. Removing the needle barrier could dramatically expand access to these life-changing treatments for obesity and diabetes. A simple pill is easier to take, easier to stick with, and frankly, far less intimidating. This convenience factor alone could unlock a market of millions who were previously put off by the prospect of regular injections.
For investors, the next few years will be a volatile but compelling watch. Clinical trial data will be scrutinised, regulatory decisions will move share prices, and the competitive jostling will be intense. Picking the ultimate winner today is a fool’s errand. The key will be to watch how these companies navigate the immense technical and commercial hurdles ahead. The firm that masters the science, scales production, and gets its pricing right could well dominate the next decade of metabolic medicine.
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
전체 바스켓 보기:Beyond The Needle: The Oral GLP-1 Revolution
2026년 9월 14일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 13일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 13일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기